Exagen Files Breast Cancer Recurrence Kit For FDA Clearance; Highlights 'Availability,' Low Cost | GenomeWeb
Exagen last week filed its breast cancer recurrence test for 510(k) clearance with the US Food and Drug Administration, hoping that the test’s ability to increase physician convenience and lower lab costs will give it an edge over competitors.
The test, eXagenBC, is in line to be the fourth genomic-based breast cancer-recurrence assay to hit the market after assays made by Genomic Health, Agendia, and Quest.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.

Pacific Biosciences is hosting a competition in which researchers are vying to win free sequencing for an organism with the most interesting genome.

An opinion piece appearing in Newsday likens familial DNA searches to stop-and-frisk policies.

The San people of Africa have drawn up a code of conduct for researchers, according to the Conversation.

In Nature this week: genotypes linked to hip osteoarthritis, and more.